Since becoming CEO of Fulcrum Therapeutics, Alex C. Sapir has made notable moves in the stock market, displaying confidence in his company’s future. His insider trading activity included significant investments in Fulcrum, peaking in July 2024 with a hefty $19.56...

Since becoming CEO of Fulcrum Therapeutics, Alex C. Sapir has made notable moves in the stock market, displaying confidence in his company’s future. His insider trading activity included significant investments in Fulcrum, peaking in July 2024 with a hefty $19.56 million purchase. Earlier transactions in early 2024 showed consistent buying activity, totaling around $1.81 million during the months of March to June. The most remarkable part is his initial stakes—he entered at a strategic time, indicating his commitment and belief in Fulcrum's potential for growth. With his recent trades and the current standing of his assets, Sapir’s wealth tied to Fulcrum stocks shows a powerful alignment between personal investment and company success.